DAY 1 - Download Presentations HERE
0820 Welcome and Chair
A/Prof Anthony Joshua, Kinghorn Cancer Centre, Sydney, Australia
0830 Phase 1 Clinical Trials – Emerging Ethical Considerations
Prof Elizabeth Eisenhauer, Queens University, Ontario, Canada
0930 The changing face of Early Phase Cancer trials
Dr Sarah Blagden, University of Oxford, United Kingdom
1030 Morning Tea
1100 Ovarian cancer as a model for clinical discovery
Prof David Bowtell, Peter MacCullum Cancer Centre, Melbourne, Australia
1145 Histomorphometrics and Radiomics in the clinic as biomarkers
Prof Anant Madabushi, Case Western University, USA
1230 Lunch
1325 Welcome to Rapid Fire Showcase Asia-Pacific
Dr Amy Prawira, Kinghorn Cancer Centre, Sydney, Australia
1330 Opportunities and challenges of early phase clinical trials in Hong Kong
Dr Herbert Loong, The Chinese University of Hong Kong
Dr Joanne Chiu, Queen Mary Hospital, Hong Kong
1400 Drug Development in New Zealand – Achievements, Opportunities and Challenges
Dr Peter Fong, Auckland City Hospital, New Zealand
1415 Phase 1 Clinical Trials: Perspective from Scientia and NECTA
Dr James Kuo, Scientia Clinical Research, UNSW, Sydney
1430 Phase 1 Clinical Trials: Perspective from Singapore
A/Prof Daniel Tan Shao Weng, National Cancer Centre, Singapore
1445 Early Drug Development at Peter Mac – local and global networks
Dr Ben Tran, Peter MacCullum Cancer Centre, Melbourne, Australia
1500 Phase 1 Clinical Trials: Perspective from Taiwan
Dr Chia-Chi (Josh) Lin, National Taiwan University Hospital, Taiwan
1515 Discussion – Advancing Trials in the Asia-Pacific
– How do we compete with USA/ Europe? Do we even care?
(Horvath, Fuller, Hausler, Thomas + Rapid Fire)
1545 Afternoon Tea
1615 Welcome to Getting to know Radionucleotides in Phase 1
Dr Charlotte Lemech, Scientia Clinical Research, UNSW, Sydney
1620 Radionucleotides in Phase 1
Dr Peter Eu, Peter MacCullum Cancer Centre, Melbourne, Australia
1645 Combinations with radionucleotides – Lessons and Future directions
A/Prof Shahneen Sandhu, Peter MacCullum Cancer Centre, Melbourne, Australia
1715 Discussion
DAY 2 - Download presentations HERE
0825 Welcome to Learning from Old things (Horvath)
Professor Lisa Horvath, Chris O’Brien Lifehouse, Sydney
0830 Moving science to new targets
Dr Hansen He, University Health Network, Toronto, Canada
0915 What do we do for chemo protection in phase 1 designs?
Dr Catherine Han, Auckland City Hospital, New Zealand
1000 Morning Tea
1030 Dosing decisions in design of phase 1 trials
Professor Steven Ackland, Calvary Mater Newcastle Hospital, NSW
1115 Impact of Genomics on Drug Development and Radiation
Professor Felix Feng, Department of Radiation Oncology, UCSF, USA
12 Lunch
CLOSED (ACADEMIC ONLY) SESSION
1300 Pipeline Presentation- MSD
1330 Pipeline Presentation- Janssen
1400 Pipeline Presentation- Abbvie
1430 Pipeline Presentation- BMS
1500 Pipeline Presentation- Merck Serono
1530 Pipeline Presentation- Amgen
1600 Pipeline Presentation- GSK
0820 Welcome and Chair
A/Prof Anthony Joshua, Kinghorn Cancer Centre, Sydney, Australia
0830 Phase 1 Clinical Trials – Emerging Ethical Considerations
Prof Elizabeth Eisenhauer, Queens University, Ontario, Canada
0930 The changing face of Early Phase Cancer trials
Dr Sarah Blagden, University of Oxford, United Kingdom
1030 Morning Tea
1100 Ovarian cancer as a model for clinical discovery
Prof David Bowtell, Peter MacCullum Cancer Centre, Melbourne, Australia
1145 Histomorphometrics and Radiomics in the clinic as biomarkers
Prof Anant Madabushi, Case Western University, USA
1230 Lunch
1325 Welcome to Rapid Fire Showcase Asia-Pacific
Dr Amy Prawira, Kinghorn Cancer Centre, Sydney, Australia
1330 Opportunities and challenges of early phase clinical trials in Hong Kong
Dr Herbert Loong, The Chinese University of Hong Kong
Dr Joanne Chiu, Queen Mary Hospital, Hong Kong
1400 Drug Development in New Zealand – Achievements, Opportunities and Challenges
Dr Peter Fong, Auckland City Hospital, New Zealand
1415 Phase 1 Clinical Trials: Perspective from Scientia and NECTA
Dr James Kuo, Scientia Clinical Research, UNSW, Sydney
1430 Phase 1 Clinical Trials: Perspective from Singapore
A/Prof Daniel Tan Shao Weng, National Cancer Centre, Singapore
1445 Early Drug Development at Peter Mac – local and global networks
Dr Ben Tran, Peter MacCullum Cancer Centre, Melbourne, Australia
1500 Phase 1 Clinical Trials: Perspective from Taiwan
Dr Chia-Chi (Josh) Lin, National Taiwan University Hospital, Taiwan
1515 Discussion – Advancing Trials in the Asia-Pacific
– How do we compete with USA/ Europe? Do we even care?
(Horvath, Fuller, Hausler, Thomas + Rapid Fire)
1545 Afternoon Tea
1615 Welcome to Getting to know Radionucleotides in Phase 1
Dr Charlotte Lemech, Scientia Clinical Research, UNSW, Sydney
1620 Radionucleotides in Phase 1
Dr Peter Eu, Peter MacCullum Cancer Centre, Melbourne, Australia
1645 Combinations with radionucleotides – Lessons and Future directions
A/Prof Shahneen Sandhu, Peter MacCullum Cancer Centre, Melbourne, Australia
1715 Discussion
DAY 2 - Download presentations HERE
0825 Welcome to Learning from Old things (Horvath)
Professor Lisa Horvath, Chris O’Brien Lifehouse, Sydney
0830 Moving science to new targets
Dr Hansen He, University Health Network, Toronto, Canada
0915 What do we do for chemo protection in phase 1 designs?
Dr Catherine Han, Auckland City Hospital, New Zealand
1000 Morning Tea
1030 Dosing decisions in design of phase 1 trials
Professor Steven Ackland, Calvary Mater Newcastle Hospital, NSW
1115 Impact of Genomics on Drug Development and Radiation
Professor Felix Feng, Department of Radiation Oncology, UCSF, USA
12 Lunch
CLOSED (ACADEMIC ONLY) SESSION
1300 Pipeline Presentation- MSD
1330 Pipeline Presentation- Janssen
1400 Pipeline Presentation- Abbvie
1430 Pipeline Presentation- BMS
1500 Pipeline Presentation- Merck Serono
1530 Pipeline Presentation- Amgen
1600 Pipeline Presentation- GSK